论文部分内容阅读
目的:研究复合磷酸脂酶治疗非酒精性脂肪性肝炎(NASH)的临床治疗效果。方法:将200例NASH患者随机分为两组,分别应用复合磷酸脂酶片和水飞蓟宾胶囊进行治疗。观察两组患者治疗前后丙氨酸氨基转氨酶(ALT)、天门冬氨酸氨基转氨酶(AST)、谷胺酰转肽酶(GGT)、甘油三酯(TG)及肝组织病理变化。结果:治疗后两组患者的肝功能及肝组织病理损害均有改善,且复合磷酸酯酶治疗组的改善效果更加明显,两组患者治疗总有效率差异具有显著性意义(<0.05)。结论:复合磷酸酯酶相对于水飞蓟宾在临床上治疗NASH具有更好的疗效。
Objective: To study the clinical efficacy of compound phosphatidyl lipase in the treatment of non-alcoholic steatohepatitis (NASH). Methods: Two hundred patients with NASH were randomly divided into two groups and were treated with compound phospholipase tablets and silybin capsules respectively. The changes of alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyl transpeptidase (GGT), triglyceride (TG) and liver histopathology were observed before and after treatment in both groups. Results: After treatment, the liver function and pathological damage of both groups were improved, and the improvement effect of compound phosphatase was more obvious. There was significant difference between the two groups in total effective rate (P <0.05). Conclusion: Compound phosphatase is more effective than silibinin in the treatment of NASH.